Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

While the broader stock market suffered steep losses amid trade policy shifts select health technology equities stood out.

"This could be a huge step." Teen scientist makes stunning breakthrough that could slash costs of lifesaving drugs: 'I cannot ...

Local pharma stocks were rocky on Friday after President Donald Trump directed major drugmakers to reduce the cost of their ...

Putnam Large Cap Value Fund posted a positive return and outperformed its benchmark, the Russell 1000 Value Index. Read more ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Banque Cantonale Vaudoise has taken a significant position in Amgen Inc. (AMGN), scooping up 15,432 shares worth about $4.81 ...

Catch top deals, trends and themes across private markets in Asia this week.

Tarrytown-based Regeneron Pharmaceuticals has reported financial results for its second quarter of 2025. Net revenues increased 4% from the $3.54 ...

The White House announced on Thursday that President Trump sent 17 major pharmaceutical companies letters delineating the ...

The pharmaceutical industry has long protested the idea of globally linked drug prices as a threat to years of U.S. dominance ...